#South Korea #Seoul #oncology #Lunit #10x Genomics

Lunit and 10x Genomics Collaborate to Enhance Cancer Research

Lunit, a prominent player in the artificial intelligence (AI) realm for cancer diagnostics, has announced an exciting partnership with 10x Genomics, a leader in single-cell and spatial biology. This collaboration aims to combine Lunit's advanced AI pathology platform, Lunit SCOPE IO, with 10x Genomics’ spatial biology technologies to enhance the discovery of oncology biomarkers.

Overview of the Collaboration

The partnership will utilize Lunit SCOPE IO to analyze Hematoxylin and Eosin (HE) pathology images in conjunction with the spatial molecular data generated through 10x Genomics’ oncology-focused clinical research. By integrating these cutting-edge technologies, researchers hope to elucidate the connections between tissue morphology and the underlying biology of tumors, thereby identifying biomarkers that can inform treatment response.

Brandon Suh, CEO of Lunit, emphasized the significance of this collaboration, stating, “10x Genomics has built powerful tools for understanding the molecular organization of tissue. Lunit SCOPE IO adds the ability to analyze the full HE landscape at scale.”

Understanding the Technology

10x Genomics is at the forefront of spatial biology, with their innovations referenced in over 10,000 research publications. Their technologies, including the Xenium and Atera platforms, provide critical insights by dissecting the molecular organization of tissue samples. When paired with Lunit SCOPE IO, which employs deep learning techniques to analyze whole-slide HE pathology images, researchers can gain a more profound understanding of tumor biology and pathology.

This integration offers the potential to not only better understand tumors but also to explore the correlation between tissue characteristics and molecular profiles in clinical settings. Roman Yelensky, the Vice President of Clinical Applications at 10x Genomics, remarked, “Spatial technologies provide a fundamentally richer view of the biology within tumors and their microenvironment.” This collaboration is expected to yield comprehensive insights that can greatly impact oncology research and subsequent treatment strategies.

Focus Areas of Research

The initial phase of this collaborative effort will support clinical studies focusing on antibody-drug conjugates and the prediction of immunotherapy responses. These studies represent a component of 10x Genomics' broader strategy to explore future diagnostic applications for spatial technologies in oncology. By examining how spatial molecular data correlates with tumour pathology, this collaboration aims to nucleate biomarker discovery that could revolutionize treatment choices.

Benefits for Clinical Research

Lunit SCOPE IO is specifically designed for research use, allowing for the deep analysis of tissue features such as tumor regions, immune-cell distributions, and tertiary lymphoid structures. When utilized alongside the spatial technologies from 10x Genomics, the analyses delivered through Lunit SCOPE IO provide additional context that enhances molecular profiling for oncology research. The potential applications are far-reaching, promising not only to enhance our understanding of cancer biology but also to further pave the way towards personalized medicine.

In summary, the collaboration between Lunit and 10x Genomics represents a significant advancement in oncology clinical research. This union of AI-powered pathology analysis and spatial biology technologies stands to offer breakthroughs in the identification of effective treatment strategies based on refined molecular insights. Additionally, it positions both companies as leaders in the continual fight against cancer, combining deep medical expertise with state-of-the-art technological advancements to usher in a new era of cancer diagnostics and treatment.

About Lunit and 10x Genomics

Founded in 2013, Lunit's mission is to conquer cancer through AI innovations. Their clinically validated solutions serve to empower earlier detection and more precise treatment across the cancer care continuum. Lunit has collaborated with an extensive network of healthcare institutions worldwide to support cancer screening and biomarker research.

On the other hand, 10x Genomics specializes in life sciences technology, offering various integrated research solutions that enable researchers to grasp biological complexity at unprecedented resolutions. Their products are essential in groundbreaking oncology, immunology, and neuroscience research, pushing the boundaries of what is understood about health and disease.

Together, these two innovators are set to make meaningful contributions toward the advancements in oncology research and patient care.